FI934849A - Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser - Google Patents

Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser Download PDF

Info

Publication number
FI934849A
FI934849A FI934849A FI934849A FI934849A FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A FI 934849 A FI934849 A FI 934849A
Authority
FI
Finland
Prior art keywords
lmwh
present
patologiskaprocesser
behandlande
sammansaettningar
Prior art date
Application number
FI934849A
Other languages
English (en)
Finnish (fi)
Other versions
FI934849A0 (fi
Inventor
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Original Assignee
Yeda Res & Dev
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9802891A external-priority patent/IL98028A/en
Priority claimed from IL98298A external-priority patent/IL98298A0/xx
Application filed by Yeda Res & Dev, Irun R Cohen, Ofer Lider, Rami Hershkoviz filed Critical Yeda Res & Dev
Publication of FI934849A0 publication Critical patent/FI934849A0/fi
Publication of FI934849A publication Critical patent/FI934849A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Surface Heating Bodies (AREA)
  • Coupling Device And Connection With Printed Circuit (AREA)
FI934849A 1991-05-02 1993-11-02 Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser FI934849A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL9802891A IL98028A (en) 1991-05-02 1991-05-02 Pharmaceuticals containing low molecular weight heparin (HWML)
IL98298A IL98298A0 (en) 1991-05-28 1991-05-28 Pharmaceutical compositions comprising a heparin derivative
PCT/US1992/003626 WO1992019249A1 (en) 1991-05-02 1992-05-01 Compositions for the prevention and/or treatment of pathological processes

Publications (2)

Publication Number Publication Date
FI934849A0 FI934849A0 (fi) 1993-11-02
FI934849A true FI934849A (fi) 1993-12-31

Family

ID=26322260

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934849A FI934849A (fi) 1991-05-02 1993-11-02 Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser

Country Status (15)

Country Link
US (3) US5474987A (de)
EP (1) EP0583360B1 (de)
JP (1) JPH06507635A (de)
KR (1) KR100235782B1 (de)
AT (1) ATE217796T1 (de)
AU (1) AU668865B2 (de)
BR (1) BR9205961A (de)
CA (1) CA2102207A1 (de)
CZ (1) CZ232593A3 (de)
DE (1) DE69232615T2 (de)
FI (1) FI934849A (de)
HU (1) HUT67136A (de)
NO (1) NO933942L (de)
SK (1) SK120193A3 (de)
WO (1) WO1992019249A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1994011006A1 (en) * 1992-11-10 1994-05-26 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
AP1390A (en) * 1996-11-27 2005-04-15 Aventis Pharmaceuticals Products Inc Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound.
AU756279B2 (en) 1997-07-14 2003-01-09 Medical Therapies Limited Agents comprising Midkine or its inhibitor as active ingredient
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (ja) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
WO2000065521A2 (en) * 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
IL154771A0 (en) * 2000-09-08 2003-10-31 Hamilton Civic Hospitals Res Antithrombotic compositions
WO2002023190A2 (en) * 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2431709A1 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
WO2003011119A2 (en) * 2001-07-31 2003-02-13 Reddy Us Therapeutics, Inc. Methods and compositions for diagnosis and treatment of vascular conditions
EP1420820A4 (de) * 2001-07-31 2005-04-06 Univ Texas Antigene von und antikörper gegen translozierte moleküle von mikroorganismen und ihre verwendungszwecke
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
WO2003088980A1 (en) * 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
AU2004208038B2 (en) 2003-01-30 2007-09-06 Prochon Biotech Ltd. Freeze-dried fibrin matrices and methods for preparation thereof
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
WO2006071794A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
EP1641913B1 (de) 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Aus der nabelschnur abgeleitete postpartum zellen und deren herstellungsmethoden und verwendung
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
CA2540699A1 (en) * 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
US20060293275A1 (en) * 2004-03-29 2006-12-28 Toshikazu Nakamura Hgf production accelerator containing heparin-like oligosaccharide
WO2006023487A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Rapid two-step synthesis of anti-coagulants
MX2008000974A (es) * 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
AU2006292224B2 (en) 2005-09-19 2013-08-01 Histogenics Corporation Cell-support matrix and a method for preparation thereof
WO2009141821A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
CA1226816A (en) * 1982-12-20 1987-09-15 Moses J. Folkman Inhibition of angiogenesis
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
US4889808A (en) * 1985-10-01 1989-12-26 American Home Products Method of enchancing t-PA and SCU-PA production
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
EP0245813B2 (de) * 1986-05-16 2000-03-22 ITALFARMACO S.p.A. Heparine, frei von E.D.T.A., Fraktionen und Fragmente von Heparin, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, welche diese enthalten
WO1988000017A1 (en) * 1986-06-27 1988-01-14 Boon Corporation Pty. Ltd. Mat
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
AT500533B8 (de) * 2000-04-13 2007-02-15 Man Nutzfahrzeuge Ag Gas- oder trolleybus

Also Published As

Publication number Publication date
SK120193A3 (en) 1994-07-06
CA2102207A1 (en) 1992-11-03
DE69232615T2 (de) 2003-01-30
US5474987A (en) 1995-12-12
FI934849A0 (fi) 1993-11-02
JPH06507635A (ja) 1994-09-01
DE69232615D1 (de) 2002-06-27
EP0583360A4 (de) 1994-04-06
US5686431A (en) 1997-11-11
AU668865B2 (en) 1996-05-23
EP0583360A1 (de) 1994-02-23
BR9205961A (pt) 1994-07-26
HUT67136A (en) 1995-02-28
HU9303110D0 (en) 1994-01-28
WO1992019249A1 (en) 1992-11-12
EP0583360B1 (de) 2002-05-22
US5908837A (en) 1999-06-01
NO933942D0 (no) 1993-11-01
KR100235782B1 (ko) 1999-12-15
ATE217796T1 (de) 2002-06-15
AU1913192A (en) 1992-12-21
CZ232593A3 (en) 1994-07-13
NO933942L (no) 1993-12-14

Similar Documents

Publication Publication Date Title
FI934849A (fi) Sammansaettningar foer foerhindrande och/eller behandlande av patologiskaprocesser
ES2192667T3 (es) Tratamiento de los trastornos de la artritis, artritis reumatica y manifestaciones asociadas con los trastornos reumaticos.
EP0675899A4 (de) NEUE INHIBITOREN VON FAKTOR Xa.
ATE150469T1 (de) Mitogenfreie substanz, deren herstellung sowie verwendung
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
NO177785C (no) Analogifremgangsmåter for fremstilling av terapeutisk aktive alkoksy-4(1H)-pyridonderivater
PT921787E (pt) Regime de administracao de inibidores de atpase de h',k'
SE9600716L (sv) Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
ES2173858T3 (es) Analogos de huperzina a.
TJ252B (en) Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv
Rouse et al. Host defense mechanisms against infectious bovine rhinotracheitis virus: II. Inhibition of viral plaque formation by immune peripheral blood lymphocytes
ES535798A0 (es) Proceso para la fabricacion de compuestos de espiro-hidantoina.
EE9900044A (et) Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviks ja vältimiseks
FR2378855A1 (fr) Nouvelles glycoproteines isolees d'hafnia, procede de preparation et application a titre de medicaments
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
Kaufmann et al. Attempts to characterize the T-cell population and lymphokine involved in the activation of macrophage oxygen metabolism in murine listeriosis
RU93058322A (ru) Композиции для предотвращения и/или лечения патологических процессов, способ применения низкомолекулярного гепарина, способ лечения
ES476703A1 (es) Procedimiento para preparar una heterovacuna para el trata -miento terapeutico del sindrome de los triconomas.
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
Cohen et al. Methods of using low molecular weight heparins treatment of pathological processes
Morales et al. Experimental immunotherapy with NK-like cells: A preliminary report
CN116687930A (zh) 吐根碱在制备防治电离辐射致放射性肺损伤药物中的应用
IWAGUCHI et al. Effect of chemotherapeutic agents on the growth of rat bladder cancer, BC-47
DK164987C (da) Anvendelse af spergualin eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel med transplantationsimmunitetsinhiberende og antiallergisk aktivitet
Gallily et al. Mouse macrophage functions under the influence of factors released by spleen cells preincubated with the methanol extraction residue (MER) tubercle bacillus fraction

Legal Events

Date Code Title Description
FD Application lapsed